Nov. 12 at 6:41 PM
$ASMB interim Phase 1b data from these two weekly‑oral dosing cohorts of ABI‑1179 (plus one monthly dosing cohort of the companion candidate ABI‑5366) are “now expected by end of year”. ABI-5366 data a few months ago was a game changer - i expect this to get run prior to or after positive data. There's really no resistance from 32 to the
$58 -
$65 area - so while its not super likely its a distinct possibility this gets run into data
